ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
This article is part of the Research TopicMolecular Pathways involved in the Pathogenesis of Diabetic Kidney DiseaseView all 6 articles
Yiqi Yangyin Huoxue Tongluo prescription ameliorates inflammatory factors in patients with stage III–IV diabetic nephropathy
Provisionally accepted
- 1First People’s Hospital of Zunyi, Zunyi, China
- 2Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Objective Diabetic kidney disease (DKD) is one of the systemic microvascular complications of diabetes mellitus, with inflammatory cytokines playing a pivotal role in its pathogenesis and progression. This study aims to investigate the clinical efficacy on inflammatory cytokines of the Yiqi Yangyin Huoxue Tongluo prescription in patients with stage III-IV DKD. Method Patients with stage III–IV DKD who were treated in our hospital between July 2022 and July 2025 were selected as the research participants. They were randomly divided into a treatment group and a control group. The patients in the control group were given routine basic treatment. The treatment group received the Yiqi Yangyin Huoxue Tongluo prescription in addition to the control group. Fasting blood glucose (FBG), serum creatinine (SCr), urea nitrogen (BUN), urinary albumin excretion rate (UAER), 24-hour urinary protein (24-h PRO), interleukin-6 (IL-6), transforming growth factor-β (TGF-β1), monocyte chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP) were measured before treatment and 2 months after treatment. Results After 2 months of treatment, compared with the control group, the treatment group exhibited significantly lower levels of FBG (P < 0.001), SCr (P = 0.013), BUN (P = 0.008), UAER (P = 0.018) and 24-h PRO (P = 0.020). Regarding inflammatory markers, the treatment group exhibited significantly lower levels of IL-6 (P = 0.012), TGF-β1 (P = 0.043) and CRP (P < 0.001) than the control group. Post-treatment scores were lower than pre-treatment scores in both groups, with the treatment group demonstrating significantly lower scores than the control group (P < 0.001). The overall response rate in the treatment
Keywords: Yiqi Yangyin Huoxue Tongluo prescription, Inflammatory factor, stage III-IV DKD, clinical efficacy, chronic kidney disease progression
Received: 23 Jun 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Cao, Li, Xiao, Gong, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenfu Cao
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.